![美股盘前:阿斯麦涨近2% 台积电斥资123亿美元“扫货”,ASML光刻机出货量将增长30%](https://i-invdn-com.investing.com/news/LYNXMPEA7H0NX_S.jpg)
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Aridis Pharmaceuticals Inc是一家处于后期阶段的生物制药公司。该公司专注于发现和开发利用全人单克隆抗体(mAbs)治疗感染的靶向免疫疗法。该公司的专有产品线由全人单克隆抗体组成,靶向与危及生命的细菌和病毒感染相关的特定病原体,主要是医院获得性肺炎(HAP)、呼吸机相关性肺炎(VAP)、囊性纤维化和COVID-19。该公司的主要候选产品AR-301针对革兰氏阳性细菌金黄色葡萄球菌(S.aureus)产生的α毒素,这是一种与HAP和VAP相关的常见病原体。其临床开发活动主要集中在AR-301、AR-712和AR-501。该公司开发的抗体发现和生产平台技术aPEXTM扩展了其现有的差异化抗体发现平台mabigail的能力。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Steven Michael Opal | - | - | Member Scientific Advisory Board |
John F. Hamilton | 78 | 2015 | Independent Director |
Jean Chastre | - | 2016 | Member of Clinical Advisory Board |
Bruno Francois | - | 2016 | Member of Clinical Advisory Board |
John S. Patton | 75 | - | Member of the Scientific Advisory Board |
Alan H. Cohen | 62 | 2017 | Member of Clinical Advisory Board |
Marin H. Kollef | 66 | 2016 | Member of Clinical Advisory Board |
Jerry Pier | - | - | Member of the Scientific Advisory Board |
David Salisbury | - | 2019 | Member of Scientific Advisory Board |
Harry B. Greenberg | - | - | Member of Scientific Advisory Board |
Susan R. Windham-Bannister | 72 | 2019 | Independent Director |
Vu L. Truong | 59 | 2003 | Founder, CEO, Chief Scientific Officer & Director |
Eric J. Patzer | 74 | 2003 | Founder & Executive Chairman |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核